Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide suspension - ORPHELIA Pharma

Next Previous
Drug Profile

Temozolomide suspension - ORPHELIA Pharma

Alternative Names: Kimozo; KIZFIZO; ORP-005; Ped-TMZ

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ORPHELIA Pharma
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Neuroblastoma
  • No development reported Cancer; Glioblastoma; Glioma

Most Recent Events

  • 03 Feb 2025 CHMP adopted negative opinion of Temozolomide suspension for Neuroblastoma in European Union
  • 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Neuroblastoma(Combination therapy, In children, Second-line therapy or greater) in France (PO, Suspension)
  • 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Neuroblastoma(In children, Second-line therapy or greater) in France (PO, Suspension)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top